# NovoCodex Biopharmaceuticals Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novocodex-biopharmaceuticals-co

- Industry: Pharmaceuticals
- Headquarters: Shaoxing, China
- Website: www.novocodex.cn
- Total disclosed funding: $121M
- Latest round: Series C (Mar 3, 2026)
- Investors on record: 13

## About

Established in 2017 and based in Shaoxing, China, NovoCodex Biopharmaceuticals Co., Ltd. is a subsidiary of a listed pharmaceuticals company Zhejiang Medicine Co., Ltd., provides innovation drugs for cancer. The company has 96 employees, including 13 doctors and 24 masters. The company was selected as a science and technology-based small and medium-sized enterprise in Zhejiang Province in 2020, and received the Shaoxing City 2020 High Quality Contribution Award and other honors. In March 2026, NovoCodex Biopharmaceuticals Co., Ltd. raised a series C funding from Dongguan Financial Holdings Group, CITIC Med Fund, Puhua Capital, Zhejiang Xinhai Asset Management, Minnesota Capital and Prosperity Investment.
The firm currently provides innovative biological drug anti-HER2, which is the first to use unnatural amino acids to insert proteins into the protein to achieve precise coupling of toxins on the monoclonal antibody molecules for the treatment of HER2 Positive recurrent breast cancer and gastric cancer. At present, the breast cancer registration clinical research of ARX788 is in the enrollment stage, and the gastric cancer registration clinical research is actively preparing. ARX305 is currently in the pre-clinical evaluation and research stage, and it is expected to submit an IND registration application in 2022. In addition, the technology platform that the company have many products under development.
The company's revenue is generated by providing innovative biological drugs.
The Series C funding will primarily be used for the clinical research and development and industrialization of the company's HER2-targeted drug.

## Funding rounds

- Series C, Mar 3, 2026 — Puhua Capital, Prosperity Investment, Dongguan Financial Holdings Group, CITIC Med Fund, Zhejiang Xinhai Asset Management
- Series B, Jul 5, 2022, $60M — Cybernaut Investment Group, Lilly Asia Ventures, China Merchants Capital, Prosperity Investment, Hongshen Capital, Zhejiang Runtu, Zhejiang Xinhai Asset Management
- Series A, Mar 18, 2021, $61M — Lilly Asia Ventures, MPC, Sanhhua Hongdao Capital, CMG-SDIC Capital Management

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- MPC — Series A
- Sanhhua Hongdao Capital (https://capitalatlas.ai/funds/sanhhua-hongdao-capital) — Series A
- CMG-SDIC Capital Management — Series A
- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Series B
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B
- Prosperity Investment — Series B, Series C
- Hongshen Capital (https://capitalatlas.ai/funds/hongshen-capital) — Series B
- Zhejiang Runtu — Series B
- Zhejiang Xinhai Asset Management (https://capitalatlas.ai/funds/zhejiang-xinhai-asset-management) — Series B, Series C
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series C
- Dongguan Financial Holdings Group (https://capitalatlas.ai/funds/dongguan-financial-holdings-group) — Series C
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series C